PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1778476
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1778476
Global Sirolimus Market Growth, Size, Trends Analysis - By Application, By Dosage, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Sirolimus Market Introduction and Overview
According to SPER market research, 'Global Sirolimus Market Size- By Application, By Dosage, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Sirolimus Market is predicted to reach 410.16 million by 2034 with a CAGR of 3.85%.
Sirolimus, sometimes referred to as rapamycin, is a macrolide compound that has antifungal and antitumor properties and is a potent immunosuppressant. It works by suppressing the immune system and allowing your body to absorb the new organ, hence preventing rejection of any organs following transplant. Sirolimus is also used to coat coronary stents, prevent organ transplant rejection in patients undergoing renal transplants, and treat Lymphangioleiomyomatosis (lung illness).
Restraints: The expansion of the global sirolimus market is being hindered by a number of negative effects, such as increased susceptibility to infection, malignancy, hypertriglyceridemia, hypercholesterolaemia, angioedema, and proteinuria. Due to potential side effects such hyperlipidaemia and hepatic artery thrombosis, sirolimus is often not given to patients receiving liver and lung transplants.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Application, By Dosage, By Distribution Channel
Regions covered
Accord Healthcare Limited, Apotex Inc, Amneal Pharmaceuticals, Inc, Actiza Pharmaceutical Private
Companies Covered
Accord Healthcare Limited, Apotex Inc, Amneal Pharmaceuticals, Inc, Actiza Pharmaceutical Private Limited, Biocon Limited, Concept Medical, Concord Biotech, Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, Livzon Pharmaceuticals Group Inc
Global Sirolimus Market Segmentation:
By Application: Based on the Application, Global Sirolimus Market is segmented as; Organ Transplant Rejection, Lymphangioleiomyomatosis, Sirolimus coated balloons and catheter devices.
By Dosage: Based on the Dosage, Global Sirolimus Market is segmented as; 0.5mg, 1mg, 2mg.
By Distribution Channel: Based on the Distribution Channel, Global Sirolimus Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online pharmacy.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
1.Introduction
- 1.1.Scope of the report
- 1.2.Market segment analysis
2.Research Methodology
- 2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
- 2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
- 2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
- 4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges
5.Market variable and outlook
- 5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
- 5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
- 5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
- 5.4.Heat Map Analysis
6.Competitive Landscape
- 6.1.Global Sirolimus Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Sirolimus Market
7.Global Sirolimus Market, By Application (USD Million) 2021-2034
- 7.1.Organ transplant rejection
- 7.2.Lymphangioleiomyomatosis (LAM)
- 7.3.Sirolimus coated balloons and catheter devices
8.Global Sirolimus Market, By Dosage (USD Million) 2021-2034
- 8.1.0.5mg
- 8.2.1mg
- 8.3.2mg
9.Global Sirolimus Market, By Distribution Channel (USD Million) 2021-2034
- 9.1.Hospital pharmacy
- 9.2.Retail pharmacy
- 9.3.Online pharmacy
10.Global Sirolimus Market, (USD Million) 2021-2034
- 10.1.Global Sirolimus Market Size and Market Share
11.Global Sirolimus Market, By Region, (USD Million) 2021-2034
- 11.1.Asia-Pacific
- 11.1.1.Australia
- 11.1.2.China
- 11.1.3.India
- 11.1.4.Japan
- 11.1.5.South Korea
- 11.1.6.Rest of Asia-Pacific
- 11.2.Europe
- 11.2.1.France
- 11.2.2.Germany
- 11.2.3.Italy
- 11.2.4.Spain
- 11.2.5.United Kingdom
- 11.2.6.Rest of Europe
- 11.3.Middle East and Africa
- 11.3.1.Kingdom of Saudi Arabia
- 11.3.2.United Arab Emirates
- 11.3.3.Qatar
- 11.3.4.South Africa
- 11.3.5.Egypt
- 11.3.6.Morocco
- 11.3.7.Nigeria
- 11.3.8.Rest of Middle-East and Africa
- 11.4.North America
- 11.4.1.Canada
- 11.4.2.Mexico
- 11.4.3.United States
- 11.5.Latin America
- 11.5.1.Argentina
- 11.5.2.Brazil
- 11.5.3.Rest of Latin America
12.Company Profile
- 12.1.Accord Healthcare Limited
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
- 12.2.Apotex Inc
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
- 12.3.Amneal Pharmaceuticals, Inc
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
- 12.4.Actiza Pharmaceutical Private Limited
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
- 12.5.Biocon Limited
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
- 12.6.Concept Medical
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
- 12.7.Concord Biotech
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
- 12.8.Dr. Reddy's Laboratories Ltd
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
- 12.9.Intas Pharmaceuticals Ltd
- 12.9.1.Company details
- 12.9.2.Financial outlook
- 12.9.3.Product summary
- 12.9.4.Recent developments
- 12.10.Livzon Pharmaceuticals Group Inc
- 12.10.1.Company details
- 12.10.2.Financial outlook
- 12.10.3.Product summary
- 12.10.4.Recent developments
- 12.11.Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
